Biphenyl and biphenyl-analogous compounds as integrin...

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C549S071000, C549S072000, C546S280400, C548S304700, C514S336000, C514S388000, C514S438000, C514S445000, C514S448000

Reexamination Certificate

active

07094911

ABSTRACT:
The present invention relates to biphenyl and biphenyl-analogous compounds, their preparation and use as pharmaceutical compositions, as integrin antagonists and in particular for the production of pharmaceutical compositions for the treatment and prophylaxis of cancer, arteriosclerosis, restenosis, osteolytic disorders such as osteoporosis and ophthalmic diseases. The compounds according to the invention have the formula (1)whereinR1, R2, U, V, A, B, W, R3, C and R4have the meaning as defined in the claims.

REFERENCES:
patent: 5238923 (1993-08-01), Connolly et al.
patent: 5393875 (1995-02-01), Branca et al.
patent: 5475013 (1995-12-01), Talley et al.
patent: 5624956 (1997-04-01), Tjoeng et al.
patent: 5736559 (1998-04-01), Himmelsbach et al.
patent: 5756545 (1998-05-01), O'Brien
patent: 5773646 (1998-06-01), Chandrakumar et al.
patent: 5852210 (1998-12-01), Chen et al.
patent: 5891912 (1999-04-01), Kawashima et al.
patent: 5914348 (1999-06-01), Kitano et al.
patent: 6040311 (2000-03-01), Duggan et al.
patent: 2112840 (1972-10-01), None
patent: 195 48 709 (1997-03-01), None
patent: 877018 (1998-11-01), None
patent: 2276161 (1994-09-01), None
patent: WO 94/12181 (1994-09-01), None
patent: WO 97/36859 (1997-09-01), None
patent: 98/26773 (1998-06-01), None
patent: WO 98/118461 (1998-07-01), None
patent: 98/35982 (1998-08-01), None
patent: WO 98 00395 (1998-08-01), None
patent: WO 99/36393 (1999-07-01), None
Burk, Mark J.; Lee, Jeffrey R.; Martinez, Jose P., Journal of the American Chemical Society, 116(23), 10847-8 (English) 1994.
Paul J Coleman et al, Expert Opinion on Therapeutic Patents 2002, vol. 12, No. 7, pp. 1009-1021.
M.E. Duggan; J.H. Hutchinson Expert Opinion on Therapeutic Patents, vol. 10, No, 9, 2000 pp. 1367-1383.
Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF, Cancer Biother Radiopharm. Apr. 2001;16(2):125-32. Medline abstract 1138959.
Neustadt, Bernard, et al., “Construction of a Family of Biphenyl Combinatoial Libraries: Structure-Activity Studies Utilizing Libraries of Mixtures”; Bioorganic & Medicinal Chemistry Letters 8 (1998) 2395-2398.
Brown, Steven L., et al.; “Stimulation of Migration of Human Aortic Smooth Muscle Cells by Vitronectin: Implications for Atherosclerosis”; Cardiovascular Research 1994:28; 1815-1820.
Brooks, Peter C., et al., “Antiintegrin αvβ3 Blocks Human Breast Cancer Growth and Angiogenesis in Human Skin”, J. Clin. Invest. ©The American Society of Clinical Investigation, Inc.; vol. 90, Oct. 1995, 1815-1822.
Brooks, Peter C., et al., “Integrin αvβ3Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels”; Cell, vol. 79, Dec. 30, 1994; 1157-1164.
Draetta, G. and Pagano, M. in “Annual Reports in Medicinal Chemistry, vol. 31”, 1996, Academic Press, San Diego, p. 241-246.
Bolton, G.L. et al, in “Annual Reports in Medicinal Chemistry, vol. 29”, 1994, Academic Press, San Diego, p. 165-174.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Biphenyl and biphenyl-analogous compounds as integrin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biphenyl and biphenyl-analogous compounds as integrin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biphenyl and biphenyl-analogous compounds as integrin... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3716157

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.